Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Momentum building. ..Going to look under couch cushions again for spare change tonight. Planning to add a few more tomorrow.
List of presenting companies at the B. Riley Conference.
http://www.meetmax.com/sched/event_23369/~public
Not attempting to connect any dots of "who's who", but couldn't help but notice that Amarantus is the only OTC ticker listed. All others appear to be Nasdaq, AMEX, ect.
So many irons in the fire...
Why pay out of pocket when grant funding is inevitable?..only IMO.
Continuing development of the MANF/PD program. A few hidden info bits about CED findings and results....
US Patent for PD Treatment of PD
WO/2014/066686 - BRAIN TARGETS FOR NEUROTROPHIC FACTORS TO TREAT NEURODEGENERATIVE DISEASE 01.05.2014 A61K 38/18
PCT/US2013/066688 AMARANTUS BIOSCIENCE HOLDINGS, INC. COMMISSIONG, John, W.
http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2014066686&recNum=1&maxRec=10&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28commissiong%29&tab=PCTDescription
International application for MANF for PD status as of 5/5/2014
http://patentscope.wipo.int/search/iasr?ia=US2013066688&PAGE=HTML&ACCESS=screen&TOK=YUbO3Yw_Xe7rLOU1IwwOS8siUHQ
AMBS. Added more today.
"This is my "post." There are many others like it but this one is mine...."
Still here. Still believe in GC, potential and eminent news. That being said....could have been a better week.
With the astounding cost of good long term care and the relatively inexpensive plans that are priced cheaper the younger you are....insurance coverage or not, I'd get the test done as soon as it is available.
I've seen too many people financially hobbled trying to maintain a quality of life for ill elderly family members. I'm guessing most everyone here has as well....
Long live the Zoom...
New Fumi blog-MANF, Wolfram, and Diabetes-Part 2
"An important article on MANF has been just published by a group in Europe. The article shows that MANF is essential for survival of pancreatic beta cells.
www.cell.com/cell-reports/abstract/S2211-1247(14)00201-0
What is MANF? As I mentioned in my previous blog, we discovered that MANF (mesencephalic astrocyte-derived neurotrophic factor) was secreted from pancreatic beta cells and neurons when their endoplasmic reticulum calcium was depleted. We also claimed that MANF could be a promising biomarker and therapeutic target for Wolfram and type 1 diabetes.
http://wolframsyndrome.blogspot.com/2014/01/manf-wolfram-and-diabetes-what-is-manf.html
Why is this article important for us? This article supports our theory that MANF is an important therapeutic target for Wolfram and diabetes! I was really encouraged by this article. Currently, we are focusing on the clinical applications of MANF in Wolfram syndrome, diabetes, and other endoplasmic reticulum-related disorders. I hope we can bring you good news soon! "
http://wolframsyndrome.blogspot.com/
I swear this was already posted last night but has since been deleted...must have been "off-topic."
If its Gerald's opinion you want... IMO i don't think he would have Tweeted the link to the study if he had any concerns about it....just my opinion.
Anyone remember when the stale reoccuring daily dig on AMBS was that...
"they only have 3 employees, are renting office space, and have no source of revenue in sight"
My how times have changed.
-Holy Sxxx what an impresive team they have put together
-Invited to occupy big pharma backed incubator at QB3.
-Lympro commercialization in sight.
I've learned that on news or update days to not even look at the stock price until at least 10am. The way AMBS has been traded for months is that the first 30 min are where the players play and scare the shares from those new to the game.
World patent search shows Commissiong patents for MANF and well as applications of MANF filed by Urano and Univ of Miami.
Does this differ from European patents?
http://patentscope.wipo.int/search/en/search.jsf
Agreed. If there is anything to the filings, EKOPX(Even Keel) and PGSGX(JPM) would make a lot more sense based on their investment strategies.
The common theory has been that institutions couldn't get involved at current prices, but were very interested once we get pps up and uplist. These filings could be indications that the institutions really are now "on deck" waiting for the same "series of events" we are waiting for. If so, when the cards are finally play it could be a true rocket ship ride for all holding.
But, I've been here a pretty long time and have seen what happens when too much anticipation is put on one particular fact or expectation. I'm in no rush. I've been adding shares for 18 months from .02 to .16 and back down again.
Even Keel Investment Funds also listed a 497 filing yesterday at 4:37. Time will tell, but the same Ihub error from 2 different funds(JPM and Even Keel) listing AMBS seems more unlikely.
http://www.evenkeelinvestments.com/
Dr. Urano's work is going to be a huge catalyst for MANF applications and associations with ophan ind. and the development of eye disease treaments. IMO.
UnivMiami Patent application for retinal disease treatment
“The receptors and signaling pathways of CDNF and MANF are unknown. While these two proteins have been considered to be potential treatments for Parkinson's disease, the inventor herein has considered them to be potential treatments for other neurodegenerative disorders, including retinal degenerative disorders, such as inherited retinal disorders, age-related macular degeneration, and glaucoma.”
http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012170918&recNum=2&maxRec=3&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28Mesencephalic+Astrocyte+Derived+Neurotrophic+Factor%29&tab=PCTDescription
Dr. Urano's Blog:
1/20/2014
Testing if MANF (mesencephalic astrocyte-derived neurotrophic factor) can suppress the ER calcium leakage-mediated neuronal cell dysfunction in Wolfram iPSC-derived neural progenitor cells.
Sunday, March 9, 2014
Patient-based therapeutics part 7- Making eye cells
I am on my way to Japan to establish a collaboration with a major Japanese medical center on our Wolfram syndrome project. Why Japan? The reason is very simple. They have a technology to make eye cells from patient-derived induced pluripotent stem cells (iPS cells). If my research group can constantly make eye cells from Wolfram syndrome iPS cells, we can understand the mechanisms of optic atrophy in Wolfram syndrome and test the efficacy of our candidate drugs using these eye cells. This is also another opportunity to raise awareness of Wolfram syndrome.
As I repeatedly mentioned in my previous blogs, Wolfram is a weapon to combat diabetes and blindness. I believe that Wolfram is an accelerated form of diabetes and blindness. Many of us will experience beta cell death and death of eye cells later in our lives. A drug that can delay the progression of Wolfram may be helpful for us when we get old.
http://wolframsyndrome.blogspot.com/
Dr. J! Long time. What are your thoughts on news today and work of Dr. Schwartz?
Kitchen+too hot for you=get out.please... Or you can suck it up and accept that you've made a educated(hopefully) decision to invest in a spec company with no revenue on the chance to make many many times your investment for doing nothing but being patient and screwing around on Ihub all day.
Impax L. having a nice jump today. Wasn't this the proposed partner Fibonocci called for a few weeks ago?
Happy bday z. Long live the zoom..
I believe the February 19th date is only referring to the Impax lab earnings conference call scheduled for the 20th.
Speculation has been made that this would be the time any AMBS/IPXL collaborations could be announced(if any exist/will exist)
Nothing concrete. Regardless, I'm going through the couch cushions again to confidently add to my position tomorrow...
Is there anymore to this you can share?
Recent Manf/Armet therapeutic research for genetic skeletal diseases:
http://hmg.oxfordjournals.org/content/early/2013/08/15/hmg.ddt383
"We demonstrate that Armet and Creld2 are genotype-specific ER stress response proteins with substrate specificities and that aggregation of mutant matrilin-3 is a key disease trigger in MED that could be exploited as a potential therapeutic target."
What role to do ARMET and CRELD2 play in genetic skeletal diseases?
http://mikebriggs1910.wordpress.com/research-overview-2/ongoing-projects/
Bingo! It's called negotiation leverage.
Regarding the presentation "to the UN" , post #89618 should clear that issue up for you. Thanks.
Yes, I think all have had your point sufficiently stamped on our foreheads...It doesn't mention "Amarantus", which is why I said that IMO there is a strong reason to speculate.
Very confidently I would expect that if it did say "Amarantus", we wouldn't be buying shares for a dime.
Soooo, if individuals feel that this speculation in strong enough, then this would be an excellent time to buy...before it possibly says "Amarantus."
While it doesn't represent lock-tight connection about the specifics of a relationship between AMBS(MANF) and Banyan(who given that their website's "latest news" is from 2012 seems rather pathetic about keeping a stream of up-to-date developments) there certainly is enough reason to strongly speculate,
"MANF significantly inhibited caspase and calpain-mediated cellular processes of cell death and conferred overall neuroprotection in our cellular model systems of TBI," said Dr. Juan Martinez, Director of Scientific Operations at Banyan Biomarkers. "This neuroprotection indicates therapeutic potential based on well-defined biochemical pathway inhibition. We look forward to working with Amarantus to further develop MANF's therapeutic potential in TBI."
http://ir.stockpr.com/amarantus/company-news/detail/574/amarantus-bioscience-and-banyan-biomarkers-to-present-poster-of-manf-data-at-the-3rd-annual-traumatic-brain-injury-conference
"The data shows that MANF has a significant ability to reduce cell death from a variety of insults that simulate Traumatic Brain Injury as we have modeled in multiple assays in our internal laboratories at Banyan," said Dr. Andreas Jeromin, PhD, Senior Director Research at Banyan, "These data give us confidence to move to the next phase of testing to further validate this approach, as well as look at innovative product development strategies to accelerate bringing a MANF-based treatment to patients for TBI."
http://www.prnewswire.com/news-releases/amarantus-biosciences-and-banyan-biomarkers-announce-positive-data-from-traumatic-brain-injury-collaboration-157732095.html
Also given that these Banyan statements were been made within the time periods that we do know Banyan has been working with DOD on TBI including a verified study involving human patients.
I have to agree. From talking with a few knowledge individuals more senior than myself "trading/day trading" used to be doing good DD and following the market. Social media, boards, ect have turned into barely more than bait and switch con-artistry. Influence the chosen direction of the day on the boards and take the money as the switch begins. ... Call a spade a spade.
Just my honest opinion...
Depending on the terms of the collaboration with Boston U./CSTE, additional funding for developing Lympro for TBI may be a non-issue, no?
http://www.bu.edu/cste/about/support-and-funding/
Support and Funding
The CSTE is grateful for financial and academic support from the following:
-The National Football League
-National Operating Committee on Standards for Athletic Equipment (NOCSAE)
-National Institute on Aging
-Health and Disability Research Institute at the BU School of Public Health
-VA New England Geriatric Research, Education, and Clinical Center
-The BU Departments of Neurology, Pathology, and Neurosurgery
-BU School of Medicine
-JetBlue
-NFL Player’s Association
-Weldon Chauffeured Transport
I'm most interested to see what the twitter chatter is after Gerald's presentation on Lympro during the emerging diagnostics session. The meeting is running behind so rather than right after lunch it looks to be a little later.
https://twitter.com/search?q=%23c4ct&src=hash&f=realtime
Nope. Good news. Twitter feeds are reading like a commercial for why a true diagnostic needs to be brought to market asap..
A live webcast of today's #C4CT Summit at @UN will be available beginning at 2pm ET here: http://webtv.un.org/
Live coverage was only scheduled for opening remarks..
Following twitter feeds is very interesting..
https://twitter.com/search?q=%23C4CT&src=hash
The webcast of today's #C4CT Summit at @UN will be available beginning at 2pm ET here: http://webtv.un.org/
The UNTV live coverage was only scheduled for opening remarks...
This is the guy that will bring the legislation and funding.
General Peter Chiarelli, United States Army (Retired)
http://1mind4research.org/staff-and-board
Gemini Program
Love that Gerald and Jack both dropped the stock symbol "AMBS" several times in the very beginning of introductions...
Looks like UN feed now up but still seems spotty. Appears that they may have delayed start until techs can fix the feed..
http://webtv.un.org
Live Blog and Twitter from Summit as provided by Dustin Fink of "Concussion Blog"
http://theconcussionblog.com/2014/01/29/c4ct-concussion-summit-2014-edition-live-blog/
https://twitter.com/concussionblog
-Apparently UN network problems, but his blogs seems active..